Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...

The U.S. faces an ongoing HIV epidemic, with women, particularly women of color, bearing a heavy burden. While there have ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

By Gift BritonFor the first time, infants younger than 28 days (neonates) can safely receive Dolutegravir (DTG), one of the most effective and widely used HIV drugs worldwide.Since the World Health ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.